JPH02503205A - Crosslinked hydrophilic copolymers for medical and paramedical applications - Google Patents
Crosslinked hydrophilic copolymers for medical and paramedical applicationsInfo
- Publication number
- JPH02503205A JPH02503205A JP1502093A JP50209389A JPH02503205A JP H02503205 A JPH02503205 A JP H02503205A JP 1502093 A JP1502093 A JP 1502093A JP 50209389 A JP50209389 A JP 50209389A JP H02503205 A JPH02503205 A JP H02503205A
- Authority
- JP
- Japan
- Prior art keywords
- product according
- copolymer
- product
- crosslinked hydrophilic
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 びパーメー゛イカル の1 コポ1マ一本発明は、医用及びパラメディカ ル用の生成物に関し、これらの用語は最も広い意味で解されるべきものであり、 “医用”は“獣医用”及び“外科用”をも包含し、“ノぐラメディカル用”は“ 治療用”、“食餌療法用”並びに“生命維持食料”用をも包含する。[Detailed description of the invention] This invention is suitable for medical and paramedical applications. With respect to products for use in the “Medical use” also includes “veterinary use” and “surgical use,” and “Nogura medical use” means “ It also includes "therapeutic", "dietary" and "life-sustaining foods".
前記の生成物は、主として、架橋アルカリ性アクリルアミド/アクリレート型又 は架橋アルカリ性ビニルアルコールアクリレート型の親水性コポリマーから成る ものであり、以下には、好ましい生成物であるアクリルアミドとアクIJ )し 酸ナトリウムとのコポリマー及びビニルアルコールとアクリル酸ナトリウムとの コポリマーについて本発明をさらに詳細力)つ個々に説明する。The products mentioned above are mainly of the cross-linked alkaline acrylamide/acrylate type or consists of a hydrophilic copolymer of the cross-linked alkaline vinyl alcohol acrylate type. The following describes the preferred products acrylamide and Acrylic IJ). Copolymers with sodium acrylate and vinyl alcohol with sodium acrylate The present invention will now be described in more detail with respect to the copolymers.
アクリルアミドとアクリル酸ナトリウムとの架橋コポリマーは、農業及び接着剤 工業のような様々な分野における用途で周知であり、カラー写真複写では粉末で 使用される。これらは、水性媒体中でゲル化する性質を有し、粉末粒度測定法に よれば、自身の体積の何百倍もの水を吸収する性質を有するものであることを言 わねばならない。Cross-linked copolymers of acrylamide and sodium acrylate are used in agriculture and adhesives It is well known for its applications in various fields such as industry, and is used as a powder in color photocopying. used. These have the property of gelling in aqueous media and are suitable for powder particle size measurement. According to this, it has the property of absorbing water hundreds of times its own volume. I have to.
製薬工業及び他の化学工業の大きな会社はすべて、例えばヘキスト、ミネソタ・ マイニング、デュポン・ド・ネモアーリコー、東し工業、ヤスア・・・は、この 種のコポリマーと関係している。All the large companies in the pharmaceutical and other chemical industries, such as Hoechst, Minnesota Mining, DuPont de Nemours Ricoh, Toshi Kogyo, Yasua... Associated with species copolymers.
本発明は、このような生成物の、極めて多様な工業分野、すなわち、前記のよう に広義の医学及びパラメディカル分野での用途に関する.これらのコポリマーは 、ヒト及び動物の生体に対して、“中性の”性質を有し、これによりこの種の適 用が可能となる。The present invention is suitable for the use of such products in very diverse industrial fields, viz. Concerning applications in the broad medical and paramedical fields. These copolymers are , has “neutral” properties towards human and animal organisms, which makes this type of It becomes possible to use
本発明は、主として、下記の基本的基:〔式中、R,、R2、R,、R″1、R ′2、R1,は同−又は異なっていてよく、水素原子又は炭素原子数1〜3のア ルキル基であり、Meはアルカリ金属を示し、ZはOH又はC O N H z 基を示す〕の架橋親水性アルカリ性コポリマーから成ることを特徴とする医用及 びパラメディカル用の生成物に関する。The present invention mainly relates to the following basic groups: [wherein R,, R2, R,, R″1, R '2, R1, may be the same or different, and are a hydrogen atom or an atom having 1 to 3 carbon atoms. alkyl group, Me represents an alkali metal, and Z is OH or C O N Hz A medical product characterized by comprising a crosslinked hydrophilic alkaline copolymer of and paramedical products.
前記のもののうち好ましい生成物は、R + = R t = R s = R ’ r−R’,−R’,−H,Me−NaでZ−CONH.のもの、すなわち 、特に下記のようなアクリルアミドとアクリル酸ナトリウムとのコポリマー あるいはR l− R t − R 2 − R ’ + = R ’ t = R ’ s − H 、 Me = NaでZ−OHOもの、すなわち、特に 下記のようなビニルアルコールとアクリル酸ナトリウムとのコポリマーこの生成 物は、乾燥状態で、好都合なことに50〜700μm、好ましくは約250μm の平均粒径を有する粉末に粉砕することができる.この形では、生成物は水性媒 体(水、血清など)又は含水−アルコール媒体の存在で自身の体積の500〜7 00倍の水を吸収してゲル化する.ゲル化の過程は、水性媒体中で最大で、最終 的な膨潤をするのに0.5〜5分かかるので、比較的迅速である.湿潤粉末は、 450〜6200am,好ましくは約3000μmの平均粒径を有する。Preferred products among the above are R+=Rt=Rs=R ' r-R', -R', -H, Z-CONH. with Me-Na. those of, i.e. , especially copolymers of acrylamide and sodium acrylate, such as: Or R l− R t − R 2 − R’ + R t = R's - H, Me = Na and Z-OHO, that is, especially This produces a copolymer of vinyl alcohol and sodium acrylate such as The material conveniently has a diameter in the dry state of 50 to 700 μm, preferably about 250 μm. It can be ground into a powder with an average particle size of . In this form, the product is produced in an aqueous medium. 500-7 of its own volume in the presence of body (water, serum, etc.) or hydrous-alcoholic medium It absorbs 00 times more water and turns into a gel. The process of gelation is maximal and final in aqueous media. It takes 0.5 to 5 minutes for the swelling to occur, so it is relatively quick. Wet powder is It has an average particle size of 450-6200 am, preferably about 3000 μm.
この粉末は、高等動物、殊に哺乳動物及びヒトに対して全体的に無害である.マ ウスについて測定された致死量は、マウスでは50であり、ラットについては体 重1kg当たり10聴を超えていた.手を触れていないウサギ及び摩擦したウサ ギの皮膚にも、ヒトの皮膚にも24時間後に炎症は認められなかった.ウサギの 目に炎症はな(、雌イヌで膣膜に炎症はなく、ウサギ、イヌ及びヒトで赤血球に 溶血作用は認められず、イヌで抗原作用は認められなかった.他の試験は、実施 例に記載する。This powder is totally harmless to higher animals, especially mammals and humans. Ma The lethal dose determined for mice is 50 and for rats it is It exceeded 10 hearings per kg of weight. Rabbits that have not been touched or have been rubbed No inflammation was observed after 24 hours in either the chicken skin or the human skin. rabbit's No inflammation in the eyes (no inflammation in the vaginal lining in female dogs, no inflammation in red blood cells in rabbits, dogs, and humans). No hemolytic effects were observed, and no antigenic effects were observed in dogs. Other tests are conducted Described in the example.
したがって、生成物は上記の様々な用途に使用することができる。The products can therefore be used in the various applications mentioned above.
次に詳細に説明する第一の用途は、例えば減量用食餌によって、病的飢餓及び肥 満に対処するものであるから、おそらく栄養士に興味深いものである.殊に、本 発明による生成物は、好ましくは丸剤に加工され、経口で吸収され、胃内で膨潤 して胃を満たし、空腹感を解消する.下記の実施例に詳細に記載するが、生成物 は生体によって吸収されず、したがって、生体に対して全く中性である.胃を満 たすことによって空腹を解消する機能が一度発揮されると、腸内で何ら変化する ことなくそのまま進行して自然の通路によって排泄される。The first use, which will be explained in detail below, is to reduce morbid hunger and obesity, for example by means of weight loss diets. It is probably of interest to dietitians, as it addresses the full spectrum of nutrition. Especially books The product according to the invention is preferably processed into pills, which are absorbed orally and swell in the stomach. fills the stomach and relieves hunger. As detailed in the Examples below, the product is not absorbed by living organisms and is therefore completely neutral to living organisms. fill the stomach Once the function of relieving hunger by eating food is activated, no changes occur in the intestines. It progresses without any problem and is excreted through natural channels.
若干の場合には、極めてわずかな緩下作用が認められ、これは前記の用途にはむ しろ好ましい特性である。In some cases, a very slight laxative effect is observed, which is of no use for the above-mentioned uses. This is a desirable characteristic.
したがって、これを減量用食餌に配合することができ、この場合に食物の大部分 を代替し、それに対応してカロリーあるいは栄養価の供給を減少することができ る。Therefore, it can be incorporated into weight loss diets, in which case the majority of the food and correspondingly reduce the supply of calories or nutritional value. Ru.
このような用途では、本発明による生成物は、加工又は考えられる製剤形に必要 なもの以外の賦形剤なしに、そのまま摂取される。In such applications, the products according to the invention are free from the necessities required for processing or for possible pharmaceutical forms. It is taken as is, without any other excipients.
別の用途は、本発明による生成物上に計算された量で、ヒトの生体に必要な栄養 素(蛋白質、脂質、グルシド、ビタミン、鉱物塩類、微量元素など)を固着させ て、生命維持食料を構成することにあり、この食料は、濃縮物又は丸剤より食欲 をそそるものであり、前記のように、胃によって示される空腹感を解消する利点 を存する。Another use is to provide the products according to the invention with calculated amounts of nutrients necessary for the human organism. Fixes elements (proteins, lipids, glucides, vitamins, mineral salts, trace elements, etc.) The purpose of this food is to constitute a life-sustaining food, which is less appetizing than concentrates or pills. It is tempting and, as mentioned above, has the benefit of eliminating the feeling of hunger indicated by the stomach. exists.
本発明による生成物の別の重要な使用分野は、健康管理の分野である.したがっ て、保健衛生のための健康管理の分野において、本発明による生成物は、通用形 式により製織材料又は不織材料の袋状物中に適切な方法で加工し、その吸収性に より包帯又は湿布として使用して、その大きい液体吸収能の利点を得ることがで きる。同じ方法で、引抜敷布、乳児又は失禁する成人のおむつを作ることができ る。また、適切な方法で生理用ナプキンあるいはパッドに加工することもでき、 この場合にはその吸収性は極めて評価されるであろう。Another important field of use of the products according to the invention is in the field of health care. Therefore Therefore, in the field of health care for health and hygiene, the products according to the invention are in common use. Processed in a suitable manner into bags of woven or non-woven material according to the formula to improve its absorbency. Can be used as a bandage or compress to benefit from its greater liquid absorption capacity. Wear. The same method can be used to make pull-out sheets, diapers for infants or incontinent adults. Ru. It can also be processed into sanitary napkins or pads using appropriate methods. In this case its absorbency will be highly valued.
医療分野では、治癒又は廠痕形成性を有する活性物質で含浸しであるいは含浸せ ずに、また、適切な袋状物に担持させて、外科用湿布又は乾式若しくは湿式プラ スターとして使用することができる。In the medical field, products impregnated or impregnated with active substances with healing or scar-forming properties are used. Surgical poultices or dry or wet plastics can also be used in a suitable bag. Can be used as a star.
特に医学的分野では、逆症療法及びホメオパシーに興味を持てば、本発明による 生成物を活性物質で含浸し、生体の表面に沈着させるか又は生体の内部にもたら すことができる。Especially in the medical field, if you are interested in allopathic medicine and homeopathy, you can use the present invention. The product is impregnated with the active substance and deposited on the surface of the organism or brought into the interior of the organism. can be done.
経口で摂取すると、生成物は、胃被膜として腸粘膜を保護し、胃炎、食道炎、胃 腸潰瘍、大腸炎、ポリポーシス、ポリープなどにおいて痛みを治療し、緩解する ことができる。When taken orally, the product protects the intestinal mucosa as a gastric lining, causing gastritis, esophagitis, gastrointestinal Treats and relieves pain in intestinal ulcers, colitis, polyposis, polyps, etc. be able to.
この同じ医学的分野で、活性物質で含浸した本発明による生成物は、内部局所投 与に使用することができ、この場合、コポリマーは活性物質をあまり速く分解し すぎるないように保護し、活性物質をそれが作用すべき場所に到達させる。In this same medical field, products according to the invention impregnated with active substances are used for internal topical administration. In this case, the copolymer does not degrade the active substance too quickly. protect the active substance from excess and allow the active substance to reach where it is supposed to act.
外用するには、活性物質で含浸した本発明による生成物は、注射によって局所に 、又は活性物質が経皮剤として作用する場合には皮膚に直接に適用することがで きる。For external use, the product according to the invention impregnated with active substances can be applied locally by injection. or can be applied directly to the skin if the active substance acts as a transdermal agent. Wear.
を負荷して(化学療法)又は放射性元素を負荷して(放射線療法)、内部又は外 部に通用することによって行うこともできる。(chemotherapy) or with radioactive elements (radiation therapy), internally or externally. This can also be done by passing it on to the department.
生成物をゲル化の開始時に液体の存在で使用する場合に、別の重要な用途は、外 科、殊に形成外科の分野にある。ゲル化後、本発明による生成物は、生体に対し て不活性で、実際に生物分解されない卓越した維持又は充填物質を提供する。Another important application is when the product is used in the presence of liquid at the beginning of gelation. in the field of plastic surgery. After gelling, the product according to the invention has no effect on living organisms. It provides an excellent maintenance or filling material that is inert and virtually non-biodegradable.
したがって、生成物をしわ、乳房下垂の治療に又は畢丸に対する補てつ物若しく はプラスチック挿入物として注射又は切開によって使用される。Therefore, the product can be used in the treatment of wrinkles, breast ptosis or as a prosthesis or is used as a plastic insert by injection or incision.
本発明は、下記の限定的でない実施例を参照すればより良く理解されるであろう 、これらの実施例は、本発明による生成物の無害性及び、したがって、前記の分 野、殊に、食餌療法及び健康管理の分野での使用の著しい容易さを証明するもの である。The invention will be better understood with reference to the following non-limiting examples. , these examples demonstrate the non-hazardous nature of the products according to the invention and therefore the aforementioned properties. demonstrating remarkable ease of use in the field, especially in the field of dietetics and health care. It is.
実施例1 消化管を通っての排泄 水で膨潤した粒子の大きさのため、粒子が腸管壁の障害を横切る可能性は極めて 少ない。Example 1 excretion through the digestive tract Due to the size of the water-swollen particles, it is highly unlikely that the particles will cross any obstruction in the intestinal wall. few.
これをチェックするため、5人の患者にミネラルウォーター250d中で予め膨 潤させたイゲタゲル(IGETAGEL、登録商標)コポリマーを、1日に10 .0 gを2回にわけて、3日間投与した。このコポリマーは、スイス国シェリ ーレン・ゼントエイチのオマレックス(OMAREX)社から入手しうる。To check this, five patients were pre-inflated in 250 d of mineral water. moistened IGETAGEL® copolymer at 10 doses per day. .. 0 g was administered in two doses for 3 days. This copolymer is produced in Schier, Switzerland. - Available from OMAREX Company of Len ZentH.
第−日日から5日間糞便を集めた。これを洗浄し、500m多孔性フィルターで 濾過した。集めた物質を観察終了時に一緒にして秤量した0回収された重量は、 5人の被検者について下記のとおりである。Feces were collected for 5 days from day -. Wash this and use a 500m porous filter. Filtered. The collected materials were weighed together at the end of the observation, and the weight recovered was: The details of the five subjects are as follows.
1、 24.6g、、 2. 26.3g、 3. 28.2g。1, 24.6g, 2. 26.3g, 3. 28.2g.
4、 25.1g、 5. 27.2g回収量の平均値は26.88 g であり、この量は、取り扱い上の損失を考慮すると、はぼ全量の生成物が排泄さ れたことを示す。4, 25.1g, 5. 27.2gThe average value of the collected amount was 26.88g This amount, considering handling losses, means that almost all of the product is excreted. Indicates that the
さらに、粒子、その形状及び構造の顕微鏡試験は、形状及び構造において当初の ものと相違を示さなかった0粒子の消化経路は、その性質及び構造を変性しない 。Furthermore, microscopic examination of the particles, their shape and structure shows that they are original in shape and structure. Digestive pathway of 0 particles showed no difference from that, does not alter its properties and structure .
実施例2 コポリマーの酵素に対する感受性の研究コポリマー粒子の試料を水と接触させて 最大の膨潤物を得た。ゲルをポルテックス(Vortex)で分散させ、so、 oo。Example 2 Study of the susceptibility of copolymers to enzymes by contacting samples of copolymer particles with water. Maximum swelling was obtained. Disperse the gel with Vortex, so. oo.
粒子/dの懸濁液を製造した。この懸濁液の試料を下記の酵素と接触させた。A suspension of particles/d was prepared. A sample of this suspension was contacted with the enzymes described below.
アミラーゼ 10.50.100ミリ当量/dトリプシン 1O150 ,100ミリ当量/Idペプシン 1O150,100ミリ当量/d懸濁 液を37℃の恒温器中で4時間保温した。保温後、細胞を数えた0回収された細 胞の数は、最初の試料全体と同じ程度であった(49250〜50015)、さ らに、遠心分離後の重量は、実験の開始時に観察されたのと同じであった。Amylase 10.50.100 meq/d Trypsin 1O150 , 100 meq/Id Pepsin 1O150, 100 meq/d suspension The liquid was kept warm in a thermostat at 37°C for 4 hours. After incubation, the collected cells were counted. The number of cells was similar to that of the whole initial sample (49,250-50,015); Moreover, the weight after centrifugation was the same as that observed at the beginning of the experiment.
水で膨潤したコポリマー粒子は、使用した酵素によって影響されなかったと思わ れる。この結果は、消化排泄に関する結果と一致する。The water-swollen copolymer particles appeared to be unaffected by the enzyme used. It will be done. This result is consistent with the results regarding digestion and excretion.
実施例3 抗原性の研究 この研究の目的は、コポリマー粒子の抗原能を測定することである。そのため、 水の存在で2.0g/日の量を5〜20日間投与する。Example 3 Antigenicity studies The purpose of this study is to determine the antigenic potential of copolymer particles. Therefore, Amounts of 2.0 g/day are administered for 5-20 days in the presence of water.
試験開始後及び終了してから4日後に、下記の試験を行った。The following test was conducted after the start of the test and 4 days after the end.
1、膨潤した物質での穿刺試験で20分後及び2時間後に皮膚の応答を判定する (即時過敏症)。1. Determine skin response after 20 minutes and 2 hours by puncture test with swollen material (immediate hypersensitivity).
λ 膨潤した物質を用いたパッチテストで24時間後及び48時間後に判定する (細胞媒介過敏症)。λ Determine after 24 and 48 hours by patch test using swollen material (Cell-mediated hypersensitivity).
すべての被検者で、試験は即時及び遅延ともに陰性であった。したがうて、コポ リマーは免疫学的に不活性であると思われる。Tests were negative both immediately and delayed in all subjects. Therefore, Kopo Rimmer appears to be immunologically inactive.
研究中20人の自発被検者のうち3人は、コポリマーの摂取後1〜2時間の間に 若干の胃の重い惑じを訴えた。しかしながら、胃痛又は腸瘍の訴えはなかった。Three of the 20 volunteer subjects during the study reported He complained of some heaviness in his stomach. However, there were no complaints of stomach pain or intestinal ulcers.
最後に、すべての自発被検者にわずかな緩下作用が認められた。Finally, a slight laxative effect was observed in all spontaneous subjects.
このような作用は、多数の被検者について全体的に認められれば、食餌療法によ る減量に関しては、逆に、消極的とは考えられないことに注目すべきである。生 理的空腹感は除かれ、腸通過は容易となる。Such an effect, if observed globally in a large number of subjects, may be due to dietary therapy. It should be noted that, on the contrary, they cannot be considered passive when it comes to weight loss. Living Physical hunger is eliminated and intestinal transit is facilitated.
実施例4 試験管内細胞挙動の研究 免疫競合細胞及び食細胞の挙動をコポリマー粒子に関して分析する。ある種の粒 径の小さい粒子は、おそらく腸壁を横切ることができるので、粒子がどうなるか ということ及び免疫機能に対する作用を研究することは有用である。Example 4 In vitro cell behavior research The behavior of immune competitive cells and phagocytic cells is analyzed on copolymer particles. some kind of grain Smaller diameter particles can probably cross the intestinal wall, so what happens to the particles? Therefore, it is useful to study the effects on immune function.
a)細胞毒性試験 濃度を増加させた膨潤粒子(20,000〜200.000)に、アレルギー患 者からのリンパ単球の一定数を加えた。AB0ヒト血清が10%存在するRPM I培地中で培養を行った。培養を4時間行った0次に、細胞にトリパン・ブルー を混合し、接触10分以内に生存細胞の数を測定した。a) Cytotoxicity test Swollen particles with increased concentration (20,000 to 200,000) are used for allergic patients. A constant number of lymphomonocytes from individuals were added. RPM with 10% AB0 human serum Culture was performed in I medium. After 4 hours of culture, cells were treated with trypan blue. were mixed and the number of viable cells was determined within 10 minutes of contact.
結果は、試料10個の平均で下記のとおりである。The results are shown below as an average of 10 samples.
生立凹皿■X 対照 93%膨潤粒子 20.00095% 膨潤粒子 100.00088% 膨潤粒子 200.00092% b)リンパ球刺激試験 リンパ単球の培養物を10個準備したが、細胞はアレルギー患者からのものであ った。Raw concave dish Control 93% swollen particles 20.00095% Swelling particles 100.00088% Swelling particles 200.00092% b) Lymphocyte stimulation test Ten lymphomonocyte cultures were prepared, but the cells were from allergic patients. It was.
RPMI培地+15%のAB血清中で5日培養を行った。Culture was performed for 5 days in RPMI medium + 15% AB serum.
培養物は下記のものである: (フィトヘムアグルチニン)刺激T−リンパ球の対照ロフト1個 PHAミドギン(レクチン、植物性メギン)を用いたロット 1個 Con−A(コンカバリンA)刺激1978球を用いたロフト1個 3種のロフトを平行して培養したが、培地1d当たり膨潤したコポリマー粒子5 0.000個を付加的に加えた sH−チミジン粒子(1,Ouc/10’細胞 )を混入した後、細胞を洗浄し、液体シンチレーションカウンター(ベンクマン )を用いてアイソトープ活性を測定した。結果を1分当たりのビート(beat ) (bpm)で示す。The cultures are: (phytohemagglutinin) 1 control loft of stimulated T-lymphocytes 1 lot using PHA midogin (lectin, vegetable meggin) 1 loft using Con-A (Concabalin A) stimulated 1978 ball Three types of lofts were cultured in parallel, with 5 swollen copolymer particles per 1 d of medium. Additional 0.000 sH-thymidine particles (1, Ouc/10' cell ), wash the cells and use a liquid scintillation counter (Venkman ) was used to measure isotope activity. The results are expressed in beats per minute. ) (bpm).
得られた結果は下記のとおりである。The results obtained are as follows.
−屁m + SE 1、 対照 369 ± 171a、 対照土粒子 375 ± 212、 PHA 76.59 3 ± 7.2502a、 PHA十粒子粒子 74,781 ± 5 .7203、 Con−A 28.513 ± 1.78 03a、 Con−A+粒子 29.557 ± 2.046統計的 分析(+スチューデントテスト)は、1と1a、2と2a13と3aとの間に統 計的有意差を示さない。-Fart + SE 1. Control 369 ± 171a, Control soil particles 375 ± 212, PHA 76.59 3 ± 7.2502a, PHA ten particles 74,781 ± 5 .. 7203, Con-A 28.513 ± 1.78 03a, Con-A+ particles 29.557 ± 2.046 statistical The analysis (+ student test) is unified between 1 and 1a, 2 and 2a, 13 and 3a. No statistically significant difference.
結局、使用した濃度ではコポリマー粒子は、試験管内でリンパ単球の細胞分裂を 妨害しない。Ultimately, at the concentrations used, copolymer particles inhibited lymphomonocyte cell division in vitro. Don't interfere.
C)食作用試験 フィコルーアイソベーク(Ficoll−1sopaque)グラディエンドで 単離したアレルギー患者からの多核細胞を洗浄し、コポ比は115であった。1 5回の実験を行った。細胞懸濁液を37℃で2時間培養した。細胞/粒子の結合 体の分離を低張水性媒体中での沈降によって行った。C) Phagocytosis test Ficoll-1 sopaque with gradient end Isolated multinucleated cells from allergic patients were washed and the copo ratio was 115. 1 Five experiments were performed. The cell suspension was incubated at 37°C for 2 hours. Cell/particle binding Separation of the bodies was performed by sedimentation in a hypotonic aqueous medium.
各試験で500個の多核細胞を数え、細胞内粒子の存在を測定した。Five hundred multinucleated cells were counted in each test and the presence of intracellular particles was determined.
粒子の食作用は観察されなかった。膨潤した粒子は、食作用が起こりそうもない 細胞よりはるかに大きい、しかし、ロゼツト型が認められた。すなわち、4〜8 個の多核細胞がおそらく食作用を試みた際に粒子の側に付着した。No phagocytosis of particles was observed. Swollen particles are less likely to undergo phagocytosis Much larger than cells, however, a rosette shape was observed. That is, 4 to 8 A few multinucleated cells attached to the side of the particle, probably during an attempt at phagocytosis.
今度は、ガラス板上で単離した単核細胞を使用して同じ試験を行った。この場合 にも、食作用は観察されなかったが、多核細胞について観察されたのと同じ型の ロゼツトが若干存在した。The same test was now performed using mononuclear cells isolated on glass plates. in this case Also, no phagocytosis was observed, but the same type of phagocytosis observed for multinucleated cells Some rosettes were present.
食細胞、多核細胞及び単核細胞は、ビニル/アクリル粒子を食すことができない 。Phagocytes, multinucleated cells and mononuclear cells cannot eat vinyl/acrylic particles .
実施例5 湿布剤 オマレックス社によって市販されているイゲタゲル(登録商標)コポリマー球を 不織布の封筒中に封入することによって40X40C1、厚さ4mの湿布剤を製 造したが、不織布の封筒は変形として伝統的なガーゼで被覆されていてもよい。Example 5 poultice Igetagel® copolymer spheres marketed by Omarex A poultice with a size of 40 x 40 C1 and a thickness of 4 m was made by enclosing it in a non-woven envelope. However, the non-woven envelope may alternatively be covered with traditional gauze.
これらの湿布剤を創傷上に適用すると、そこでは湿布剤の吸収性は伝統的湿布剤 に比べて著しく良好に発揮される。さらに、これらは、外部微生物による創傷の 感染に対する遮断剤として顕著に作用する。When these poultices are applied onto a wound, the absorbency of the poultice is comparable to that of traditional poultices. It performs significantly better than. In addition, they are used to treat wounds caused by external microorganisms. Acts significantly as a blocker against infection.
国際調査報告 EP 8900118 SA 26721 国際調査報告international search report EP 8900118 SA 26721 international search report
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH51188 | 1988-02-12 | ||
CH00511/88 | 1988-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02503205A true JPH02503205A (en) | 1990-10-04 |
Family
ID=4188685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1502093A Pending JPH02503205A (en) | 1988-02-12 | 1989-02-09 | Crosslinked hydrophilic copolymers for medical and paramedical applications |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0354948A1 (en) |
JP (1) | JPH02503205A (en) |
AU (1) | AU3049489A (en) |
WO (1) | WO1989007455A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002360222A (en) * | 2001-06-08 | 2002-12-17 | Nissei Kosan Kk | Food for suppression or prevention of obesity |
JP2011511086A (en) * | 2008-02-05 | 2011-04-07 | ウェロソフィー・コーポレーション | Absorbable oral ingestion and related methods of manufacture and use |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0569542A1 (en) * | 1991-01-31 | 1993-11-18 | Massachusetts Institute Of Technology | Interpenetrating-polymer network phase-transition gels |
UA10911C2 (en) * | 1994-08-10 | 1996-12-25 | Мале Впроваджувальне Підприємство "Іhтерфалл" | Biocompatible hydrogel |
AU740233B2 (en) * | 1998-01-09 | 2001-11-01 | Genzyme Corporation | Fat-binding polymers |
US7048917B1 (en) | 1998-01-09 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
US6299868B1 (en) | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
US6264937B1 (en) | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
US7338657B2 (en) | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
WO2001070289A2 (en) | 2000-03-20 | 2001-09-27 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
ES2551164T3 (en) | 2000-03-24 | 2015-11-16 | Biosphere Medical, Inc. | Microspheres for active embolization |
US7186419B2 (en) | 2000-08-25 | 2007-03-06 | Contura Sa | Polyacrylamide hydrogel for arthritis |
MY130475A (en) | 2000-08-25 | 2007-06-29 | Contura As | Polyacrylamide hydrogel and its use as an endoprosthesis |
US7049345B2 (en) | 2001-06-29 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
AU2006245950B2 (en) | 2005-05-09 | 2012-01-12 | Biosphere Medical S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1534771A (en) * | 1966-05-31 | 1968-08-02 | Dow Chemical Co | Weakly crosslinked copolymers, absorbing aqueous fluids stably and irreversibly |
FR2077687B1 (en) * | 1970-02-05 | 1973-03-16 | Roussel Uclaf | |
DE2935712A1 (en) * | 1978-09-07 | 1980-03-20 | Sumitomo Chemical Co | METHOD FOR PRODUCING STRONG ABSORBENT POLYMERISATES |
EP0206808A3 (en) * | 1985-06-24 | 1987-08-19 | American Colloid Company | Continuous method for preparing polyacrylate resins |
DE3767514D1 (en) * | 1986-03-11 | 1991-02-28 | Thompson Barry Antony | FEEDING CATTLE WITH POLYMERS. |
-
1989
- 1989-02-09 JP JP1502093A patent/JPH02503205A/en active Pending
- 1989-02-09 WO PCT/EP1989/000118 patent/WO1989007455A1/en not_active Application Discontinuation
- 1989-02-09 EP EP89902252A patent/EP0354948A1/en not_active Withdrawn
- 1989-02-09 AU AU30494/89A patent/AU3049489A/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002360222A (en) * | 2001-06-08 | 2002-12-17 | Nissei Kosan Kk | Food for suppression or prevention of obesity |
JP2011511086A (en) * | 2008-02-05 | 2011-04-07 | ウェロソフィー・コーポレーション | Absorbable oral ingestion and related methods of manufacture and use |
US9457048B2 (en) | 2008-02-05 | 2016-10-04 | Wellosophy Corporation | Absorbent ingestible agents and associated methods of manufacture and use |
US9867847B2 (en) | 2008-02-05 | 2018-01-16 | Wellosophy Corporation | Absorbent ingestible agents and associated methods of manufacture and use |
Also Published As
Publication number | Publication date |
---|---|
EP0354948A1 (en) | 1990-02-21 |
WO1989007455A1 (en) | 1989-08-24 |
AU3049489A (en) | 1989-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02503205A (en) | Crosslinked hydrophilic copolymers for medical and paramedical applications | |
Pieper et al. | Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids | |
Kumar et al. | Psyllium mucilage and its use in pharmaceutical field: an overview | |
CN108578756A (en) | A kind of function sanitary pad and preparation method thereof | |
Eldad et al. | The cost of an extensive burn survival | |
Hess | The antirachitic activation of foods and of cholesterol by ultraviolet irradiation | |
Cuzzell et al. | Wound care: Trial & error yields to knowledge | |
Sathasivampillai | The role of honey in pediatric treatments in Sri Lankan Siddha Medicine | |
CN104688769B (en) | Compound montmorillonite povidone iodine ointment and its preparation method and application | |
CN105595346B (en) | A kind of liquid preparation and preparation method thereof for replenishing the calcium | |
CN107595819A (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
WO1990004611A1 (en) | Copolymers of vinyl alcohol with vinyl acetate, cross-linked by glutaric dialdehyde, method of obtaining them and a pharmaceutical preparation based thereon | |
Orsolic et al. | Antimetastatic effect of honey. | |
JP2014513721A (en) | “RENESSANS”, a pharmaceutical composition having antibacterial, antiulcer and immunomodulating effects | |
Kirschner | CHLOROPHYLL as THERAPY–Cancer–Germs-Intestines | |
CN108392572A (en) | A kind of plaster and its preparation method and application that expelling the stasis for the new sore relieves the pain | |
RU2795869C1 (en) | Method for preventing recurrence of chronic diseases of the oral mucosa after orthopedic treatment with removable orthopedic structures | |
CN112245411B (en) | Universal oral bandage and preparation method thereof | |
CN116549489A (en) | Antibacterial repair debridement gel and preparation method thereof | |
Herrick et al. | CHRONIC ACETANILID POISONINGWITH REPORT OF A CASE DUE TO ABSORPTION OF THE DRUG FROM AN ULCER OF THE LEG. | |
Smithies | THE FREQUENCY OF PROTOZOIC ENTEROCOLITIS IN THE MIDDLE WEST: CLINICAL MANIFESTATIONS, DIAGNOSIS AND TREATMENT. 1 | |
EP0775450A2 (en) | Dietetic compositions comprising chitosan | |
RU2158124C1 (en) | Composition for fixing removable prostheses | |
van Marle, J. & Franz | Acute acalculous cholecystitis in critically ill patients-case reports | |
CN1172689C (en) | Medicine containing pittosporum glabratum lindl extract as active components for curing pulmonary tuberculosis |